Novo and Lundbeck have reduced R&D intensity
While a number of international companies in the past five years have reinvested an increasingly larger part of their revenue in R&D, the opposite trend is evident at two of Denmarks largest pharmaceutical companies. But new strategies may change this fact in the coming years.
The world’s largest pharmaceutical companies collectively spend an increasingly larger part of their revenue on research and development (R&D), but the opposite development can be traced for the two largest pharmaceutical companies in Denmark, measured by revenue.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
